Company / PP&E (Net)
Charles River Laboratories PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.7B
FY2025
5-year range
$1.3B / $1.7B
FY2021-FY2025
Trend
+3.2%
vs FY2024
Sector context
#33 of 138
Health Care
What the data says
Charles River Laboratories's pp&e (net) of $1.7B is higher than 76% of companies in the Health Care sector (FY2025).
Based on SEC 10-K filings.
$1.7B in FY2025 with a 5-year CAGR of +8.0%. Top quartile in the Health Care sector.
Remained stable around $1.7B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +4.1%
- 5-Year CAGR
- +8.0%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 138This company $1.7B Sector average $1.4B
▼
+17.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +8.0%, indicating consistent growth.
- In FY2025, pp&e (net) increased 3.2% year-over-year.
- Ranks #33 out of 138 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7B | +3.2% |
| FY2024 | $1.6B | -2.2% |
| FY2023 | $1.6B | +11.9% |
| FY2022 | $1.5B | +13.5% |
| FY2021 | $1.3B | +14.8% |
| FY2020 | $1.1B | +20.5% |
| FY2019 | $932.9M | +0.0% |
| FY2018 | $932.9M | +19.3% |
| FY2017 | $782.0M | +3.5% |
| FY2016 | $755.8M | +11.5% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026